Evidence map›Paper›PMID 42078344›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Exploring provider preferences in the design of HIV treatment packages integrating long-acting injectable antiretroviral therapy in New York Ryan White Part A medical case management programs: A discrete choice experiment.

Rebecca Zimba, Elizabeth A Kelvin, Sarah Kulkarni, Jennifer Carmona, Tigran Avoundjian, Connor Emmert, Meghan Peterson, Mary Irvine, Denis Nash

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Rebecca ZimbaCUNY Institute for Implementation Science in Population Health, City University of New York, New York, NY, USA.ORCID 0000-0001-5278-3930
Elizabeth A KelvinCUNY Institute for Implementation Science in Population Health, City University of New York, New York, NY, USA.ORCID 0000-0002-0566-8697
Sarah KulkarniCUNY Institute for Implementation Science in Population Health, City University of New York, New York, NY, USA.ORCID 0000-0002-0807-339X
Jennifer CarmonaDivision of Disease Control, New York City Department of Health and Mental Hygiene, New York, NY, USA.ORCID 0009-0002-7240-9625
Tigran AvoundjianCUNY Institute for Implementation Science in Population Health, City University of New York, New York, NY, USA.ORCID 0000-0001-6202-2043
Connor EmmertBureau of HIV, Hepatitis, and Sexually Transmitted Infections, New York City Department of Health and Mental Hygiene, New York, NY, USA.ORCID 0009-0008-9691-1146
Meghan PetersonBureau of HIV, Hepatitis, and Sexually Transmitted Infections, New York City Department of Health and Mental Hygiene, New York, NY, USA.
Mary IrvineBureau of HIV, Hepatitis, and Sexually Transmitted Infections, New York City Department of Health and Mental Hygiene, New York, NY, USA.ORCID 0000-0003-1852-7559
Denis NashCUNY Institute for Implementation Science in Population Health, City University of New York, New York, NY, USA.ORCID 0000-0002-3280-5386

Funding

Assessing Perceptions and Preferences around Long-acting Injectables (APPLI) in the Ryan White HIV/AIDS ProgramR34MH126809 · NIMH · GRADUATE SCHOOL OF PUBLIC HEALTH AND HEALTH POLICY · PI IRVINE, MARY KATHRYN, NASH, DENIS · 2021 to 2023
$619k
NIMH NIH HHS R34 MH126809
6 · The paper itself

Abstract

Introduction: Understanding provider preferences for the design of HIV treatment packages could enhance the implementation of programs to support the adoption of long-acting injectable antiretroviral therapy (LAI ART) by people living with HIV who are interested in initiating this treatment modality. Methods: We recruited providers from New York City (NYC), Rockland, Putman, and Westchester County Ryan White Part A Medical Case Management (MCM) programs to complete a discrete choice experiment (DCE) containing twelve tasks with two alternatives and an opt-out option, with additional survey questions about implementation readiness and choice motivations. The alternatives included four attributes-Type of ART Medication (monthly or bimonthly LAI ART), Service Location and Mode, Support for Clients, and Rewards for Clients-with 2-4 levels each. We ran latent class multinomial logit analyses (LCA) with 1-5 classes to estimate preferences and explore hypothesis-free preference heterogeneity. We estimated attribute influence using relative importances and preferences using zero-centered part-worth utilities for each level. Results: One hundred seventy-seven providers completed the survey (July 2022-January 2023). About half (52%) were 40-59 years old, 72% identified as women, and the plurality (41%) identified as Latino/a. We chose the two-group LCA solution. Bimonthly LAI ART was preferred over monthly LAI ART overall and in both groups. Group 1 (n=45) preferred more traditional adherence supports (e.g., injections at the clinic by appointment, injection appointment reminders) whereas Group 2 (n=132) preferred more client-centered supports (e.g., injections at home by appointment, free transportation to injection appointments if at a clinic). Both groups preferred higher monetary value gift cards for clients for every on-time injection. The top-ranking motivations indicated that participants prioritized patient convenience over job satisfaction and administrative or financial feasibility for the agency. The scores for all implementation measures indicate readiness to implement LAI ART in both groups. Conclusions: Our implementation science-focused study suggests that providers of MCM services in NYC and surrounding counties are motivated to offer services to support clients' access and adherence to LAI ART. More work is needed to understand how programs have, in fact, integrated supports for LAI ART into their services.

Indexed as

Antiretroviral therapyDiscrete choice experimentHealthcare providersHIVLong-acting injectablesNew York

Identifiers

PMID42078344
PMCPMC13131762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.